Stay updated on SAGE-217 Safety in MDD Insomnia Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.

Latest updates to the SAGE-217 Safety in MDD Insomnia Clinical Trial page
- Check5 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2 and the Back to Top element was removed. No substantive changes to core content, pricing, stock, or time-related information.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, and a 'Back to Top' feature has been added.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has updated its facility name and location details, specifically highlighting St. Louis, Missouri, and added drug information for zuranolone, while removing previous references to depression and related terms.SummaryDifference2%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check41 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check48 days agoChange DetectedThe web page has been updated to a new version (v2.16.10), and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
Stay in the know with updates to SAGE-217 Safety in MDD Insomnia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.